Jianfeng Group Lin2016 -002 (Announcement on Withdrawal of Two Drug Registration Applications by Subsidiates)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2016-002
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Prompt Announcement
on Withdrawal of Two Drug Registration Applications by Subsidiaries
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Recently, china food and drug administration (hereinafter referred to as "State Food and Drug Administration") issued the Announcement on Withdrawal of 199 Drug Registration Applications by 128 Enterprises (2016 21 ), zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), a subsidiary of the Company, withdrew the registration application of 2 drugs. The relevant information is hereby announced as follows:
Basic Information of 1. Products
(I) Cefapirin Sodium for Injection
Drug Name |
Cefapirin Sodium for Injection |
acceptance number |
CXHS1200117 , CXHS1200118 |
Dosage Form |
Chinese Pharmacopoeia Dosage Form Injection |
Application Phase |
Production |
Specification |
0.5g , 1.0g |
Registration Classification |
Chemical Drug 3.1 Class |
Applicant |
Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical Group Corporation Sichuan Antibiotic Industry Research Institute |
2008 January 17, 148, the company obtained the "Drug Clinical Trial Approval" issued by State Food and Drug Administration ; 2011# On January 10, 151, the company completed the clinical trial of the drug. On May 23, 2012, the company applied for production to State Food and Drug Administration .
(II) mitiglinide calcium capsule| drug name |
mitiglinide calcium capsule |
| acceptance number |
CXHS1400304 |
| dosage form |
Chinese Pharmacopoeia Dosage Capsule |
| Application Stage |
Production |
| Specification |
10mg/ |
| Registration Classification |
Chemical 3.1 Class |
| Applicant |
Zhejiang Jianfeng Pharmaceutical Co., Ltd., China Pharmaceutical University |
December# On the 8th of 253, the company obtained the "Drug Clinical Trial Approval" issued by State Food and Drug Administration ; 2012# On April 5, 256, the company completed the clinical trial of the drug; On December 30, 2014, the company applied for production to State Food and Drug Administration . Other Relevant Situations of 2. Drugs
Cefapirin Sodium for Injection is the first generation cephalosporin, which is suitable for respiratory system infection, urinary system infection, skin and soft tissue infection, wound infection, otolaryngology infection, intracavitary infection, etc. caused by sensitive bacteria. Up to now, the company has invested about 1089 .65 million yuan in the drug research and development project.
Mitiglinide Calcium Capsules improve postprandial hyperglycemia in Ⅱ
diabetic patients by stimulating insulin secretion. Up to now, the company has invested about 549.71 million yuan in the drug research and development project. Market Status of Similar Drugs in 3.
Production Unit |
Dosage Form |
Specification |
|
Yantai Zhengfang Pharmaceutical Co., Ltd. |
Capsule | 10mg |
|
Liaoning Huarui United Pharmaceutical Co., Ltd. |
Tablet | 5mg | , 10mg
|
Zhengda Qingchunbao Pharmaceutical Co., Ltd. |
Tablet | 5mg | , 10mg
|
Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd. |
Tablet | 5mg | , 10mg
|
Jiangsu Haosen Pharmaceutical Co., Ltd. |
Tablet | 10mg |
|
Beijing Sihuan Kebao Pharmaceutical Co., Ltd. |
Tablet | 5mg |
|
Up to now, there is no domestic manufacturer of cefapirin sodium for injection listed.
4. Sales Data, Production and Usage
Cefapirin Sodium for Injection Major foreign manufacturers are Japan Bristol Company and
Bristol-Myers Squibb(Bristol-Myers) Company; Up to now, there are no similar products on the market in China. The main foreign manufacturers of mitiglinide calcium capsules are Japan's Kissei Pharmaceutical Company (Kissei). Company has not found the specific production, sales data and usage of the above-mentioned similar products from public channels. Impact of
5. on the Company and Risk Prompt
Company voluntarily withdrew the registration application of the above 2
drugs according to the latest policy of the State Food and Drug Administration on drug review and approval, and in combination with the current situation of domestic drug clinical trials and the recommendations of clinical trial institutions and contract research organizations, the decision was made after careful consideration.The withdrawal of the registration application will not have a significant impact on the company's current operating results, but will increase the development time and uncertainties of related products. please the majority of investors rational investment, pay attention to investment risk.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
January 21, 2016
More information
The company organized "charity one day donation"
On the morning of October 22, in the lobby on the first floor of Jianfeng Building, all cadres and employees of the group headquarters and subordinate enterprises working in Jianfeng Building participated in the 2021 "Charity Day Donation" activity to offer their love to Jinhua charity. In the next few days, the company's subordinate enterprises also organized "charity one-day donation" activities one after another.
2021
11-01
The company organizes new employee induction training
"Growth is more important than success. I hope everyone can become the backbone and pillars of the peak as soon as possible." On September 2, Yu Jianhong, general manager of the group company, put forward ardent hopes in the face of new employees. On the 2nd and 3rd, the group company organized induction training for new employees recruited in the past year. The group company chairman Jiang Xiaomeng, general manager Yu Jianhong and other leaders and relevant department heads gave lectures to them.
2021
09-13
Daye Peak: Typical Regional Industrial Green Development
On August 23, Huangshi Radio and Television Station broadcast the special program of "Strengthening Overall Planning and Promoting Energy Saving and Emission Reduction in Industrial Field". Daye Jianfeng Cement Company, as a typical enterprise with outstanding achievements in establishing green factories and energy saving and emission reduction in Huangshi area, appeared in the program.
2021
09-01
Yunnan Peak Helps Border Epidemic Prevention and Control
On August 22, Yunnan Peak Cement Company, through the Red Cross Society of Pu'er City and the Epidemic Prevention Headquarters of Pu'er City, donated vacuum insulation pots with a total value of 800000 yuan to the four border counties for the prevention and control of the new coronary pneumonia epidemic in the border area, and supported the prevention and control of the epidemic at the border with practical actions.
2021
09-01
Group Party Committee to Learn "July 1" Important Speech
On August 13, the party committee of the group company held a special meeting to collectively study General Secretary Xi Jinping's important speech at the celebration meeting of the 100 anniversary of the founding of the Communist Party of China, convey the requirements of the party committee at a higher level, and make arrangements for organizing party members of the company to study the "July 1" speech.
2021
08-23
Spike Ranked 2020 China's Top 100 Cement Clinker Production Capacity
Recently, the company received the "2020 China Cement Clinker Production Capacity Top 100" plaque issued by China Cement Network. The ranking of China's top 100 cement clinker production capacity is organized and evaluated by China Cement Network, an authoritative information platform for the domestic cement industry. It is released according to the actual clinker production capacity of each cement enterprise at the end of last year. The company has been ranked in the top 100 list for many consecutive years.
2021
08-23
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page